Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3855 - Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Novel Carcinoembryonic Antigen (CEA) T-cell Bispecific Antibody (CEA-CD3 TCB) for the Treatment of CEA-Positive Solid Tumors


11 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Clinical Research


Ignacio Melero


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


I. Melero1, N.H. Segal2, J. Saro3, W. Ros4, M. Martinez-Garcia5, G. Argiles6, V. Moreno7, S. Ponce8, A. Marabelle9, J.M. Cleary10, H.I. Hurwitz11, J.P. Eder12, C. Jamois13, E. Andersson14, S. Bouseida13, F. Sandoval13, M. Bacac3, T. Nayak13, V. Karanikas3, E. Calvo15

Author affiliations

  • 1 Immunology And Immunotherapy Department, CIMA, CUN University of Navarra, 31009 - Pamplona/ES
  • 2 Department Of Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 3 Roche Pharmaceutical Research And Early Development, Roche Innovation Centre, Zurich/CH
  • 4 Molecular Pathology, The Netherlands Cancer Institute, Amsterdam/NL
  • 5 Medical Oncology Department, Hospital del Mar, Barcelona/ES
  • 6 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 7 Start Madrid-fjd, Hopital Fundacion Jimenez Diaz, 28040 - Madrid/ES
  • 8 Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid/ES
  • 9 Département D’innovation Thérapeutique Et D’essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif/FR
  • 10 Early Drug Development Center, Dana-Farber Cancer Institute, Boston, MA/US
  • 11 Duke Cancer Institute, Duke University Medical Center, 27710 - Durham/US
  • 12 Early Drug Development Program, Yale University Cancer Center New Haven Hospital, New Haven, CT/US
  • 13 Roche Pharmaceutical Research And Early Development, Roche Innovation Centre, Basel/CH
  • 14 Roche Pharmaceutical Research And Early Development, Roche Innovation Centre, Munich/DE
  • 15 Early Phase Program, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid/ES


Abstract 3855


CEA-CD3 TCB (RG7802, RO6958688) is a novel T-cell bispecific antibody targeting CEA on tumor cells and CD3e on T cells. In mouse models, CEA-CD3 TCB displays potent anti-tumor activity, leads to increased intratumoral T cell infiltration and activation and up-regulates the PD-L1/PD-1 pathway.


Biodistribution was assessed in mice using SPECT/CT. Patient (pt) samples were from 2 dose-escalation studies in CEA-positive solid tumors. Study 1 (S1): single agent weekly (qw) (0.052-600 mg IV; n = 80), and Study 2 (S2): CEA-CD3 TCB qw (5-160 mg IV) plus atezolizumab 1200 mg q3w (n = 46). Analytics: [CEA-CD3 TCB]—bifunctional PK assay; antidrug antibodies—ELISA; immunophenotyping in peripheral blood (PB)—flow cytometry (FCM), in baseline (BSL) and on-treatment (OT; week 7) biopsies by immunohistochemistry and FCM; plasma cytokines—multiplex assay; PD-L1—SP142 assay.


In mice, CEA-CD3 TCB preferentially accumulated in CEA-positive tumors. CEA-CD3 TCB showed near-linear PK in both studies (S1: 35; S2: 28). In pts with matched BSL and OT biopsies, 7/10 CRC pts treated with ≥ 60 mg of CEA-CD3 TCB in S1 had > 2.4-fold increase in CD8 T cells, which did not correlate with RECIST response. In S2, 2/2 CRC pts receiving ≥ 80 mg of CEA-CD3 TCB (with RECIST reduction ≥ 25%), showed > 8-fold increase in CD8/Ki67 T cells. SUVmax decrease (FDG-PET) correlated with BSL levels of CD4-OX40 and CD8-PD1 in S1 and CD8-OX40 in S2. In PB at week 4, a > 4-fold expansion of activated CD8 T cells (HLA-DR/Ki67) but not CD4, was detected in most pts at doses ≥ 60 mg (S1: 24; S2: 9). In most pts, increases in IL-6 were seen after the first TCB infusion and in fewer cases after the second/third infusion in both studies (S1: 62; S2: 33).


On-treatment increases in intratumoral CD8 T cells consistent with the mechanism of action and support that CEA-CD3 TCB is the first tumor-targeted T cell bispecific showing biological activity. The activation level of intratumoral T cells at BSL could be a predictive biomarker of response. In preclinical models, tumor targeting has been demonstrated. Updated data will be presented. Clinical data are reported separately.

Clinical trial identification


Legal entity responsible for the study

F Hoffmann-La Roche Ltd.


F Hoffmann-La Roche Ltd.


I. Melero: Advisory board: Bristo-Myers Squibb, Roche-Genentech, AstraZeneca, Lilly, Merck Serono, Bayer, Genmab, Alligator, Bioncotech, Tusk Grants from: Roche-Genetech, Bristo-Myers Squibb, Bioncotech. N.H. Segal: Consulting and research funds from Genentech/Roche. J. Saro: Employee of Roche and stock holder of Roche. A. Marabelle: PI: Roche, Bristo-Myers Squibb, Merck, Pfizer, Lytix pharma, Eisai, AstraZeneca/Medimmune Scientific Consulting: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi, BioNTech. J.M. Cleary: Research funding to the institution from Merrimack Pharmaceuticals, Taiho Oncology, Merck, Roche, Abbvie, Precision Biologics, and Bristo-Myers Squibb. H.I. Hurwitz: Honoraria: Roche and Lilly. Consultant: Roche, Bristo-Myers Squibb, Lilly, Novartis, Incyte, TRACON Pharma, Acceleron Pharma, GlaxoSmithKline, OncoMed. Institutional Funding: Roche, GlaxoSmithKline, Novartis, TRACON Pharma, Bristo-Myers Squibb, Regeneron, Lilly, Macrogeneics, NCI. C. Jamois, S. Bouseida, F. Sandoval, V. Karanikas: Roche employee. E. Andersson: RICM participation in the Roche Connect program. M. Bacac: Employed by Roche and own stock options. T. Nayak: Roche stocks. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.